SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$245M
Q2 2024
Positions
68
Filings on Record
25
2019–present window
Filed
Aug 15, 2024
original filing

Summary

Altium Capital Management LLC reported $245M in U.S.-listed holdings across 68 positions for Q2 2024.

Its largest position, VERA, represents 10.5% of the portfolio.

Compared with Q1 2024, the fund opened 20 new positions and exited 26.

Portfolio Metrics

Turnover
+44.2%
vs prior filed quarter
Top-10 Concentration
+55.9%
share of reported value
Largest Position
+10.5%
Vera Therapeutics
New / Exited
20 / 26
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $266MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 86.0%Other: 9.6%ADR: 4.0%Equity WRT: 0.4%
  • Common Stock · 86.0% · $211M
  • Other · 9.6% · $23M
  • ADR · 4.0% · $10M
  • Equity WRT · 0.4% · $872,312

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SRPTSAREPTA THERAPEUTICS INCNEW+81.9K81.9K+$13M$13M
SKYESKYE BIOSCIENCE INCNEW+1.35M1.35M+$11M$11M
ARGXARGENX SENEW+23.0K23.0K+$10M$10M
AVADEL PHARMACEUTICALS PLCNEW+610.0K610.0K+$9M$9M
CTNMCONTINEUM THERAPEUTICS INCNEW+429.3K429.3K+$8M$8M
RZLTREZOLUTE INCNEW+1.70M1.70M+$7M$7M
MLTXMOONLAKE IMMUNOTHERAPEUTICSNEW+115.0K115.0K+$5M$5M
OTLKOUTLOOK THERAPEUTICS INCNEW+501.8K501.8K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

64 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1VERAVERA THERAPEUTICS INChistory →CL A10.54%$26M714.0K
2ADMAADMA BIOLOGICS INChistory →COM6.89%$17M1.51M
3XENEXENON PHARMACEUTICALS INChistory →COM5.74%$14M360.6K
4INTRA-CELLULAR THERAPIES INCCOM5.39%$13M193.0K
5SRPTSAREPTA THERAPEUTICS INChistory →COM5.28%$13M81.9K
6INSMINSMED INChistory →COM PAR $.015.19%$13M190.0K
7ALIMERA SCIENCES INCCOM NEW4.88%$12M2.15M
8SKYESKYE BIOSCIENCE INChistory →COM NEW4.41%$11M1.35M
9ARGXARGENX SEhistory →SPONSORED ADR4.04%$10M23.0K
10SOLENO THERAPEUTICS INCCOM3.54%$9M212.9K
11AVADEL PHARMACEUTICALS PLCCOM SHS3.50%$9M610.0K
12CN2CATALYST PHARMACEUTICALS INChistory →COM3.16%$8M500.0K
13CTNMCONTINEUM THERAPEUTICS INChistory →CL A3.08%$8M429.3K
14RZLTREZOLUTE INChistory →COM NEW2.98%$7M1.70M
15ASNDASCENDIS PHARMA A/Shistory →SPONSORED ADR2.78%$7M50.0K
16VKTXVIKING THERAPEUTICS INChistory →COM2.64%$6M122.0K
17SVRASAVARA INChistory →COM2.59%$6M1.57M
18ZVRAZEVRA THERAPEUTICS INChistory →COM NEW2.32%$6M1.16M
19MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD2.06%$5M115.0K
20LRMRLARIMAR THERAPEUTICS INChistory →COM2.05%$5M693.0K
21XTNTXTANT MED HLDGS INChistory →COM NEW1.91%$5M7.42M
22AXSMAXSOME THERAPEUTICS INChistory →COM1.64%$4M50.0K
23REALTHE REALREAL INChistory →COM1.63%$4M1.25M
24CYBIN INCCOM1.54%$4M13.95M
25OTLKOUTLOOK THERAPEUTICS INChistory →COM1.51%$4M501.8K
26RAREULTRAGENYX PHARMACEUTICAL INhistory →COM1.17%$3M70.0K
27ORICORIC PHARMACEUTICALS INChistory →COM1.17%$3M405.0K
28VERU INCCOM0.78%$2M2.28M
29CATXPERSPECTIVE THERAPEUTICS INCCOM NEW0.78%$2M191.4K
30MISTMILESTONE PHARMACEUTICALS INCOM0.55%$1M1.01M
31ACHVACHIEVE LIFE SCIENCES INCCOM0.41%$1M216.3K
32ALLURION TECHNOLOGIES INCCOM SHS0.39%$967,512969.8K
33BIOVIE INCCL A NEW0.32%$793,9281.98M
34CNTXCONTEXT THERAPEUTICS INCCOM0.29%$721,802360.0K
35KARYOPHARM THERAPEUTICS INCCOM0.26%$642,024740.0K
36FAT BRANDS INC*W EXP 07/16/2020.23%$569,000200.0K
37APREAPREA THERAPEUTICS INCCOM NEW0.23%$558,392137.2K
38SPRUCE BIOSCIENCES INCCOM0.17%$419,941811.2K
39EVOKE PHARMA INCCOM NEW0.15%$366,301692.4K
40BOLDBOUNDLESS BIO INCCOM0.13%$321,78783.1K
41LXRXLEXICON PHARMACEUTICALS INCCOM NEW0.08%$204,936122.0K
42INTELLIGENT BIO SOLUTIONS INCOM0.07%$161,10083.9K
43PMNTPERFECT MOMENT LTDCOM SHS0.06%$135,09562.8K
44NXGLWNEXGEL INC*W EXP 12/01/2020.04%$98,325225.0K
45CEMTREX INCCOM NEW0.03%$74,791340.0K
46WEARABLE DEVICES LTD*W EXP 09/14/2020.03%$70,0151.41M
47QUOIN PHARMACEUTICALS LTDSPONSORED ADS0.02%$59,814103.1K
48ONFOWONFOLIO HOLDINGS INC*W EXP 01/02/2020.02%$49,760200.0K
49RCKTWROCKET PHARMACEUTICALS INC*W EXP 09/02/2020.02%$44,406731.6K
50NEXALIN TECHNOLOGY INC*W EXP 99/99/9990.01%$35,700105.0K
51APPLIED DNA SCIENCES INCCOM NEW0.01%$35,18486.2K
52VSEEWVSEE HEALTH INC*W EXP 99/99/9990.01%$32,460150.0K
53MOBIX LABS INC*W EXP 99/99/9990.01%$26,820150.0K
54NLS PHARMACEUTICS LTD*W EXP 02/02/2020.00%$6,900200.0K
55BNCWWCEA INDUSTRIES INC*W EXP 02/11/2020.00%$3,750250.0K
56CYCUWWESTERN ACQSTN VENTURES CORP*W EXP 99/99/9990.00%$3,660100.0K
57CINGWCINGULATE INC*W EXP 12/10/2020.00%$2,916270.0K
58BTMWQBITCOIN DEPOT INC*W EXP 06/30/2020.00%$2,36550.0K
59JEFFS BRANDS LTD*W EXP 99/99/9990.00%$2,19868.7K
60CONDUIT PHARMACEUTICALS INC*W EXP 09/22/2020.00%$1,550100.0K
61COLISEUM ACQUISITION CORP*W EXP 08/22/2020.00%$1,41728.3K
62SRZNWSURROZEN INC*W EXP 08/01/2030.00%$1,36582.2K
63SELINA HOSPITALITY PLC*W EXP 10/27/2020.00%$1,101101.4K
64TCBWFTC BIOPHARM HOLDINGS PLC*W EXP 02/10/2020.00%$23518.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$266M98Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.